Highest-materiality recent filing
Lumvoa is the first FDA-approved treatment for TED with labeling covering both active and chronic disease.
Viridian Therapeutics Annual Meeting approves director elections, KPMG ratification, say-on-pay
Tomas Kiselak and Jennifer K. Moses elected as Class II directors until 2029.
Viridian pre-pays $55.1M Hercules Capital loan, terminates credit facility
Paid ~$55.1M to satisfy all principal, accrued interest and fees under Loan Agreement with Hercules Capital.
Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug
Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.
Viridian raises ~$359M via $250M convertible notes and $117M equity offering
Issued $250M aggregate principal of 1.75% Convertible Senior Notes due 2032; initial conversion price ~$24.65/share.
Viridian Q1 net loss $104.9M; veligrotug PDUFA June 30, elegrobart positive data, BLA Q1 2027
Cash $762.2M at March 31, 2026, down from $874.7M at Dec 31, 2025; net loss $104.9M vs $86.9M YoY.
Proptosis responder rate at week 24: 50% (Q4W) and 54% (Q8W) vs 15% placebo; both p<0.0001.
REVEAL-1 met primary endpoint with 54% proptosis responder rate for elegrobart Q4W vs 18% placebo at week 24 (p<0.0001).
Viridian reports 2025 net loss of $342.6M; veligrotug PDUFA date June 30, 2026
Cash, cash equivalents and marketable securities were $874.7M as of Dec 31, 2025, up from $717.6M.
Viridian closes $289M equity, $300M royalty financing; BLA submitted for veligrotug in TED
Cash position ~$887.9M as of Oct 31, 2025, up from $490.9M at Sep 30, after equity, royalty, and debt financings.
Viridian Therapeutics priced 11.4M-share offering at $22/sh for ~$251M gross proceeds
Offering of 11,425,000 shares at $22.00/share; underwriters have 30-day option for up to 1,713,750 additional shares.
Viridian expects ~$490.9M cash as of Sept 30, 2025; preliminary, unaudited
Preliminary cash, equivalents, and marketable securities of ~$490.9M as of September 30, 2025.
Viridian Therapeutics secures up to $600M via royalty sale and debt facility
DRI Healthcare pays $55M upfront for U.S. revenue rights; up to $300M total tied to VRDN-003 milestones and FDA approval.
Viridian reports cash of $563.4M; BLA for veligrotug on track for 2H 2025
Cash, cash equivalents and short-term investments $563.4M as of June 30, 2025, down from $636.6M at March 31, 2025; runway into 2H 2027.
Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.
Viridian shareholders approve 8M-share increase in equity plan in close vote
Stockholders narrowly approved amendment to increase equity plan shares by 8,000,000 (35.3M for, 35.1M against).
Viridian: 70% of veligrotug proptosis responders maintain response at week 52 in THRIVE trial
70% of veligrotug proptosis responders (21/30) in THRIVE maintained response at week 52, defined as ≥2 mm reduction from baseline without fellow eye worsening.
Viridian Q1 cash $636.6M; veligrotug BLA on track for H2 2025
Cash, cash equivalents, and short-term investments $636.6M at March 31, 2025, down from $717.6M in December 2024; runway into H2 2027.
Viridian appoints Jeff Ajer to board; grants stock options to 14 new employees
Jeff Ajer, former BioMarin CCO with 25+ years rare disease experience, appointed to VRDN board effective April 7, 2025.
Viridian Therapeutics appoints Christopher Cain to board; Peter Harwin resigns effective March 10
Christopher Cain (Director of Research, Fairmount Funds Management) named Class I director and chair of Nominating and Corporate Governance Committee.
Viridian Therapeutics enters $300M ATM equity offering with Jefferies; terminates prior $175M ATM
New Open Market Sale Agreement with Jefferies LLC allows sale of up to $300M in common stock.
Viridian reports positive phase 3 data for veligrotug in TED; cash $717.6M
Veligrotug met all primary and secondary endpoints in THRIVE and THRIVE-2 for active and chronic TED.
Viridian Therapeutics promotes Seth Harmon to CFO effective Jan 1, 2025
Seth Harmon, previously SVP of Finance and Accounting and Principal Financial Officer, appointed CFO effective Jan 1, 2025.
Viridian's veligrotug meets all primary & secondary endpoints in Phase 3 THRIVE-2 chronic TED trial
Proptosis responder rate 56% vs 8% placebo (48% adj, p<0.0001); 2.34mm mean reduction vs 0.46mm.
Viridian Q3 net loss $76.7M; positive phase 3 TED data, VRDN-008 best-in-class NHP profile
Q3 net loss $76.7M vs $47.7M YoY; cash $753.2M, net proceeds $243.2M from Sep offering; runway into H2 2027.
Viridian Therapeutics raises ~$258.8M in public offering of common and Series B preferred stock
10,666,600 common shares at $18.75/share and 20,000 Series B non-voting convertible preferred shares at $1,250.06250/share offered.
Proptosis responder rate 70% drug vs 5% placebo; mean reduction 2.9 mm vs 0.5 mm (p<0.0001).
Viridian Q2 net loss $65M; THRIVE topline readout on track for Sept 2024; cash $571.4M
Net loss of $65.0M in Q2 2024 vs $55.1M Q2 2023; cash balance $571.4M as of June 30, 2024.
Viridian Therapeutics posts updated investor presentation on website
Updated corporate presentation available on company website, dated July 2024.
Viridian shareholders approve 2M share increase for equity plan; directors elected
Amendment to 2016 equity plan approved (32.2M for, 24.3M against), adding 2M shares to reserve.
Viridian Therapeutics Q1: THRIVE TED trial enrollment completed (113 pts); topline data Sept 2024
Cash, cash equivalents, and short-term investments of $613.2M as of March 31, 2024, sufficient into H2 2026.
Viridian Therapeutics amends lease for new headquarters suite, extends term 5 years
Fourth Amendment to Lease for 10,427 rentable sq ft at 221 Crescent St, Waltham, MA.
Viridian reports $645.7M cash, $237.7M net loss; VRDN-001 Phase 3 readouts mid-2024
Cash, cash equivalents and short-term investments ~$645.7M as of Jan 31, 2024 (preliminary), extending runway into H2 2026.
Viridian raises ~$150M in stock offering, reports $477M cash, outlines VRDN-003/001 trial timelines
Raised ~$150M gross from 7.14M shares at $21.00; underwriters have 30-day option for 1.07M additional shares.
Viridian promotes Tom Ciulla to CMO; details 2024 TED trial timelines and FcRn milestones
Dr. Thomas Ciulla promoted to CMO, succeeding Dr. Barrett Katz who becomes consultant; Dr. Katz receives severance and consulting fee.
Viridian selects VRDN-003 as lead SC program for TED; half-life 40-50 days, pivotal mid-2024
VRDN-003 showed extended half-life of 40-50 days, 4–5× longer than VRDN-001.
Viridian Q3 net loss $47.7M; new CEO Mahoney; cash runway into 2026 after $185M placement
Net loss $47.7M vs $28.9M YoY; R&D $30.4M (+$8.3M) and G&A $20.9M (+$12.0M).
Scott Myers resigned from the board effective Oct 29, 2023; departure not due to any disagreement with the company.
Viridian Therapeutics announces new CEO, $185M private placement, next-gen FcRn inhibitors
Stephen Mahoney appointed President and CEO, succeeds Scott Myers. Base salary $650k, 55% bonus target, option for 1.26M shares.
Viridian appoints Agios CMO Dr. Sarah Gheuens to Board of Directors
Board expanded from 5 to 6 directors; Gheuens appointed Class I director until 2025 annual meeting.
Viridian Therapeutics CFO Kristian Humer resigns; Seth Harmon appointed principal financial officer
Kristian Humer, CFO and CBO, resigns effective Sept 12, 2023; eligible for severance under existing agreement.
Viridian posts updated investor presentation on website; contents not detailed in filing
Presentation dated July 2023 titled 'Corporate Overview' made available via 8-K.
Viridian announces positive Phase 1/2 data for VRDN-001 in chronic TED; THRIVE trial amended
VRDN-001 showed mean proptosis reduction of 1.6 mm (combined doses) at week 6; proptosis responder rate 42%.
Viridian shareholders approve 2M share increase to 2016 Equity Plan at annual meeting
Stockholders approved amendment to 2016 Equity Incentive Plan, increasing share reserve by 2,000,000 shares.
Viridian Therapeutics Q1 net loss $68.2M; VRDN-001 chronic TED data expected June/July 2023
Net loss of $68.2M for Q1 2023 vs. $25.7M in Q1 2022; R&D expenses $50.7M including $15M upfront to Enable Injections.
Viridian Therapeutics COO Carrie Melvin departs effective April 11, 2023
Carrie Melvin ceased as COO effective April 11, 2023; severance benefits provided per employment agreement.
Viridian Therapeutics discloses de minimis cash holdings at Silicon Valley Bank
Company holds low single digit millions of USD in cash and equivalents at Silicon Valley Bank.
Viridian Q4 2022 net loss $45.8M, cash $424.6M; THRIVE Ph3 enrolled
Net loss $45.8M in Q4 2022 vs $28.9M in Q4 2021; R&D expense $39.3M vs $22.4M.
Viridian Therapeutics appoints Scott Myers as President and CEO, succeeding Jonathan Violin
Scott Myers, former CEO of AMAG Pharmaceuticals, appointed President & CEO and Class III Director effective Feb 6, 2023.
3 mg/kg cohort: 67% proptosis responders, 56% overall responders, 67% achieved CAS 0/1, 20% complete diplopia resolution at week 6.
On April 2, 2025, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”), appointed Jeff Ajer to serve as a Class I director of the Company, effective as of April 7, 2025.
On March 5, 2025, Peter Harwin, a member of the Board, notified the Company of his decision to resign as a member of the Board effective as of March 10, 2025.
appointed Christopher Cain, Ph.D., the Director of Research at Fairmount Funds Management LLC, to serve as a Class I director of the Company, chairperson of the Nominating and Corporate Governance Committee, and member of the Audit Committee and Science & Technology Committee, effective as of March 10, 2025.
On January 7, 2025, the Board of Directors of Viridian Therapeutics, Inc. (the “Company”) appointed Seth Harmon to serve as the Chief Financial Officer of the Company effective as of January 1, 2025.
The Board of Directors of the Company appointed Dr. Thomas Ciulla, formerly the Company’s Chief Development Officer since February 2023, as Chief Medical Officer of the Company effective January 3, 2024.
On January 3, 2024, after discussions with Viridian Therapeutics, Inc. (the “Company”) regarding his future plans, Dr. Barrett Katz, age 74, transitioned to a consulting role and ceased to serve as Chief Medical Officer of the Company.
On October 29, 2023, Scott Myers resigned as a member of the board of directors (the "Board") of Viridian Therapeutics, Inc. (the "Company"), effective immediately.
Mr. Mahoney was also appointed to the Company’s Board of Directors (the “Board”) as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company’s President and Chief Executive Officer, effective immediately.
Effective September 21, 2023, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed a new director, Dr. Sarah Gheuens, to serve as a Class I director to hold office until the 2025 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified.
On September 8, 2023, Kristian Humer, the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics, Inc. (the “Company”), resigned, effective September 12, 2023.
on September 12, 2023, Seth Harmon, the Company’s Senior Vice President of Finance, assumed the role of the Company’s principal financial and accounting officer.
Max materiality 0.95 · Median 0.70 · Most common event other_material